A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment.
New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a new survey entitled “Understanding Obstructive Sleep Apnea Treatment Experiences and Patient Perspectives.” According to the data gathered May 28-29, 2024, 69 percent of patients with obstructive sleep apnea (OSA) are willing to switch to a pill-form treatment, with ease of use being cited as the top reason to switch by 84 percent of patients willing to switch.
Sleep apnea lacks an FDA-approved, medicated treatment. Currently, 60 percent of OSA patients use a positive airway pressure (PAP) device, of which a CPAP is the most common type. However, patient satisfaction around these machines is mixed, with more than half of patients reporting that they are either dissatisfied or neutral about their treatment.
The survey also found that 61 percent of OSA patients who use a CPAP or other PAP machine report multiple disruptions to their sleep every week, with almost 70 percent of patients reporting that the machine is uncomfortable. Additionally, 37 percent of patients said their current treatment either had no change or worsened their overall quality of life, with another 31 percent reporting similar results on their sleep quality.
“The U.S. market for sleep apnea devices is expected to substantially increase from $2.02 billion in 2023 to $3.76 billion by 2032,” said Ari Zoldan, CEO of Quantum Research Group, LLC. “That staggering compound annual growth rate of 7.12 percent over such a short time frame demonstrates not only the size of the market for sleep apnea treatments but also the significant unmet need evident in the lack of an FDA-approved, medicated treatment for this condition.”
For example, Incannex (NASDAQ: IXHL)is developing a pill-form treatment for OSA. The Phase 2/ 3 FDA IND-enabling RePOSA pivotal trial is underway after dosing began in May. This trial follows closely on the heels of positive Phase 2 data that demonstrated IHL-42X reduced the Apnea Hypopnea Index (AHI), which measures obstructive sleep apnea, by an average greater than 50 percent at the low dose. The study also found that 25 percent of patients’ AHI score declined by more than 80 percent.
IHL-42X is a fixed-dose combination of dronabinol, an FDA-approved form of synthetic delta-9 tetrahydrocannabinol, with the carbonic anhydrase inhibitor acetazolamide. Both have individually shown promise in treating obstructive sleep apnea in off-label use via previous studies, but are now shown to work synergistically together.
“Despite being the standard treatment, studies show that there is low compliance with CPAP machines, and this survey further confirms the need for treatment alternatives,” said Joel Latham, president and CEO of Incannex. “We look forward to advancing our clinical program in the hopes of bringing a medicated treatment option to market, a solution that we believe patients will find more convenient and comfortable.”
The Quantum Research survey also found that 37 percent of OSA patients either don’t use their PAP device every night or sometimes remove it overnight. The most common annoyances with these devices include mask discomfort (69 percent), dry mouth or throat (53 percent) and air leaks (47 percent).
The complete data is available here via Quantum Research Group’s website.
About Quantum Research Group, LLC
Quantum Research Group, LLC is a global consultancy firm that integrates investor relations, public relations and equity research into a unique hybrid approach to deliver measurable results to publicly traded companies on the NASDAQ, NYSE and AMEX stock exchanges. Their distribution partners include dozens of leading financial platforms.
Disclosures
Quantum Research Group, LLC is being compensated by Incannex for providing media coverage and research materials regarding them and their securities. Investors can find company-specific and/ or macro-related risk factors in the respective financial filings of Incannex.
Statements within this report may constitute forward-looking statements involving many uncertainties and risk factors around the named businesses, industry and macroeconomic environment. All data covered in this report is based on a survey conducted by Quantum Research Group, LLC on behalf of Incannex in April 2024, and no investment recommendations are made within the resulting report on that survey or this press release.
This report and press release do not take into account individual investor circumstances or preferences. Investors must do their due diligence and be aware of the high degree of risk in biotechnology stocks and small-cap equities, including the potential for a complete loss of their investment.
Quantum Research Group, LLC may be compensated for non-research-related services, including issuing press releases and securing media coverage, writing articles, and providing investor relations services and other additional services. The costs associated with non-research-related services are dependent on the terms of the contract with each individual company. Issuers are not required to engage us for these additional services.
Quantum Research Group’s research is based on publicly available information and no investment recommendations are made within this report.
CONTACT:
Jessica Daitch
jessica@quantum-corp.com
https://www.quantum-corp.com/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222150
